Teva Pharmaceutical Industries revenue and financials
$39.13Change from previous close: −1.34%Absolute change: −$0.53
In the fiscal year ended December 2025, Teva Pharmaceutical Industries reported revenue of $17.26B (+4.32% year over year). Net income was $1.41B, a net margin of 8.2%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +4.32%
- 2025 vs 2024
- Net margin
- 8.2%
- 2024: -9.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1,649 | 1,247 | 1,368 | 1,590 | 798 | 1,216 | 748 | 2,446 | 2,225 | 3,890 |
| Depreciation and amortization | 1,002 | 1,059 | 1,153 | 1,308 | 1,330 | 1,557 | 1,722 | 1,842 | 2,112 | 1,524 |
| Capital expenditure | -501 | -498 | -526 | -548 | -562 | -578 | -525 | -651 | -874 | -901 |
| Investing cash flow | 737 | 792 | 968 | 656 | — | — | — | — | — | — |
| Financing cash flow | -2,151 | -1,791 | -1,913 | -1,487 | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | -12.0 | -901 | -1,303 |
| Share repurchases | — | — | — | — | — | — | — | — | 0.0 | 0.0 |
| Debt issued | 2,298 | 0.0 | 3,151 | 0.0 | — | — | — | — | — | — |
| Debt repaid | -4,112 | -1,641 | -4,852 | -1,369 | — | — | — | — | — | — |
| Effect of exchange rates | 21.0 | -174 | -30.0 | -123 | — | — | — | — | — | — |
| Net change in cash | 235 | 247 | 423 | 759 | — | — | — | — | — | — |
| Free cash flow | 1,148 | 749 | 842 | 1,042 | — | — | — | — | — | — |